胸腺肽α1治疗慢性阻塞性肺疾病稳定期的的疗效观察.docVIP

胸腺肽α1治疗慢性阻塞性肺疾病稳定期的的疗效观察 　　【摘要】目的:观察胸腺肽α1治疗慢性阻塞性肺疾病稳定期的临床疗效。方法:将100例慢性阻塞性肺疾病稳定期患者随机单盲分为2组,治疗组在常规综合治疗基础上加用胸腺肽α11.6mg皮下注射,隔日1次(qod),疗程共半月,对照组采用常规综合治疗,观察两组治疗前后临床肺功能和实验室指标改善情况。两组治疗3月后总结临床疗效。结果:治疗组肺功能、氧分压、二氧化碳分压、pH、临床症状、TLC、CD?+4、CD?+8、CD?+4/CD?+8等改善明显优于对照组,而且无明显不良反应。治疗组、对照组治疗3月后总有效率分别为88%、64%。结论:在常规治疗基础上加用胸腺肽α1治疗慢性阻塞性肺疾病稳定期,临床疗效明显提高。 　　【关键词】慢性阻塞性肺疾病稳定期;胸腺肽α1 　　 　　The Clinical Observation of Thymosin-α1 on treatment 　　of stable phase of Chronic Obstructive Pulmonary Disease 　　HUANG Wen?ting OU Yang?fan WEI Li?Juan CHEN Ping 　　【Abstract】ObjectiveThis study was conducted to observe the effectof Thymosin-α1 on treatment of stable phase of Chronic Obstructive Pulmonary Disease.MethodsIn a partially randomized single-blind clinical trial, 100 patients with stable phase of chronic obstructive pulmonary disease patients were divided into control and treatment groups. In the conventional treatment group based on the combined treatment with thymosin α11.6mg,qod, Half a month for a course of treatment.the control group using conventional integrated treatment,The two groups were observed before and after treatment the laboratory indicators and lung function to improve the situation.Both groups 3 months after concluding the treatment of.clinical.efficacy.Results.the.lung.function,PO2,PCO2,PH,clinicalsymptoms,TLC,CD?+4,CD?+8,CD?+4/CD?+8,etc.of the treatment group have significantly improved better than the control group,and no significant adverse reactions. 3 months after treatment,treatment group,control group,respectively,the total effective rate was 88%、64%.ConclusionCombination of thymosin α1 with conventional treatment improves significantly efficacy of stable phase of chronic obstructive pulmonary disease . 　　【Key words】stable phase of chronic obstructive pulmonary disease;thymosin α1 　　【中图分类号】R563 【文献标识码】A 【文章编号】1006-1959(2009)08-0099-02 　　 　　慢性阻塞性肺部疾病(简称COPD)是一种具有气流受限特征的可以预防和治疗的疾病,气流受限不完全可逆、呈进行性发展,与肺部对香烟烟雾等有害气体或有害颗粒的异常炎症反应有关。目前普遍认为COPD以气道、肺实质和肺血管的慢性炎症为特征,在肺的不同部位有肺